Increase (Decrease) in Deferred Income Taxes
Regeneron Pharmaceuticals Increase (Decrease) in Deferred Income Taxes decreased by 58.7% to $96.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 31.0%, from $139.10M to $96.00M. Over 4 years (FY 2021 to FY 2025), Increase (Decrease) in Deferred Income Taxes shows an upward trend with a 52.0% CAGR.
Analysis
How to read this metric
An increase suggests tax expenses were recorded but not yet paid, while a decrease indicates the utilization of deferred tax assets or payment of previously deferred liabilities.
Detailed definition
Represents the non-cash impact on operating cash flow resulting from timing differences between financial reporting and...
Peer comparison
Common across all capital-intensive industries; peers often show fluctuations based on tax legislation and capital investment cycles.
operating_increase_decrease_in_deferred_income_taxesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$41.70M | -$7.00M | $205.90M | $225.00M | $156.00M | $85.70M | $279.70M | $216.50M | $209.30M | $125.70M | $286.30M | $190.40M | $118.10M | $168.60M | $280.20M | $139.10M | $135.20M | $278.60M | $232.50M | $96.00M |
| QoQ Change | — | +83.2% | >999% | +9.3% | -30.7% | -45.1% | +226.4% | -22.6% | -3.3% | -39.9% | +127.8% | -33.5% | -38.0% | +42.8% | +66.2% | -50.4% | -2.8% | +106.1% | -16.5% | -58.7% |
| YoY Change | — | — | — | — | +474.1% | >999% | +35.8% | -3.8% | +34.2% | +46.7% | +2.4% | -12.1% | -43.6% | +34.1% | -2.1% | -26.9% | +14.5% | +65.2% | -17.0% | -31.0% |
Increase (Decrease) in Deferred Income Taxes at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's increase (decrease) in deferred income taxes?
- Regeneron Pharmaceuticals (REGN) reported increase (decrease) in deferred income taxes of $96.00M in Q1 2026.
- How has Regeneron Pharmaceuticals's increase (decrease) in deferred income taxes changed year-over-year?
- Regeneron Pharmaceuticals's increase (decrease) in deferred income taxes decreased by 31.0% year-over-year, from $139.10M to $96.00M.
- What is the long-term trend for Regeneron Pharmaceuticals's increase (decrease) in deferred income taxes?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's increase (decrease) in deferred income taxes has grown at a 52.0% compound annual growth rate (CAGR), from $147.10M to $785.40M.
- What does increase (decrease) in deferred income taxes mean?
- The change in cash flow caused by differences between when taxes are recorded for accounting and when they are paid to authorities.